Plain Aspirin

ApprovedSmall molecule

HHamad Medical Corporation

Plain Aspirin is one of 66 small molecule programs targeting Adverse Effect. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EffectActive, not recruiting

Ischemic StrokeActive, not recruiting

Adverse EffectPreclinical

Active, not recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Plain Aspirin

HHamad Medical Corporation

Approved

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 7

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Adverse Effect

NCT06541691

Clinical

Trials by Indication[1]

Resistance1 trial

Enteric Coating as a Factor in Aspirin Resistance

Completed·RRoyal College of Surgeons, Ireland··NCT00531362·250 enrolled

Ischemic stroke1 trial

An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.

Completed·HHamad Medical Corporation·Phase 4·NCT04330872·42 enrolled

Adverse Effect1 trial

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Recruiting·RRajaie Cardiovascular Medical and Research Center·N/A·NCT06541691·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Plain Aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plain Aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plain Aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamad Medical Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHamad Medical Corporation

Plain Aspirin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Resistance1 trial

Ischemic stroke1 trial

Adverse Effect1 trial

References

Drug Info

Quick Facts

Related News